Background:

UCB9608 (UCB-9608) is a potent, selective, orally bioavailable PI4KIIIβ inhibitor with IC50 of 11 nM; also shows an IC50 of 37 nM in the human mixed lymphocyte reaction (HuMLR) assay, only inhibits the PI4KIIIβ and PI3KC2 α, β and γ lipid kinases in apnel of 250 kinases tested at 10 uM; UCB9608 is vastly more soluble, selective compound with improved metabolic stability and excellent pharmacokinetic profile, significantly prolongs allogeneic organ engraftment in vivo.

参考文献:
1. Reuberson J, et al. J Med Chem. 2018 Jun 28. doi: 10.1021/acs.jmedchem.8b00521.